Main methadone side effects

Methadone co-administration: definition

We chose the term “co-administration” rather than “low-dose methadone” or “co-analgesia.”

Methadone co-administration refers to adding methadone, usually at a low dose, to an ongoing opioid regimen while maintaining the other opioid, without performing a complete opioid switch to methadone. This strategy is also described in the literature as add-on methadone, adjunctive methadone, or methadone as a coanalgesic.

In clinical practice, the doses used are generally low, most commonly around 5–20 mg/day. A threshold of 30 mg/day is frequently used in the literature to define low-dose methadone strategies, but this should be considered a pragmatic cut-off rather than a strict pharmacological boundary.

Working definition: the addition of methadone, usually at a low dose and up to approximately 30 mg/day, to an opioid that is continued concurrently, with the aim of improving pain control and/or limiting escalation of the primary opioid dose.

The term “low dose” primarily describes a low methadone dosage and does not specify the therapeutic strategy. Methadone may, for example, be prescribed at a low dose as the primary opioid, particularly in opioid-naïve patients.

The term “co-analgesia”, although frequently used in the literature, is broader. It generally refers to the combination of several analgesic treatments acting through different mechanisms. This is common in cancer pain management and therefore does not specifically describe the practice of combining methadone with another opioid.

Finally, although 30 mg/day is commonly used in the literature as a pragmatic definition of low-dose methadone, most co-administration studies and clinical practices report substantially lower doses, typically in the range of 5–20 mg/day.

Methadone co-administration: rationale

Methadone co-administration is based on the distinctive pharmacological profile of methadone, which extends beyond its opioid activity. In particular, methadone acts as an NMDA receptor antagonist, which may help reduce central sensitization, opioid tolerance, and some neuropathic or refractory pain components.

This pharmacodynamic complementarity is one of the main rationales for adding low-dose methadone to an existing opioid regimen.

Methadone co-administration: advantages

Low-dose co-administration makes it possible to benefit from methadone’s analgesic properties with lower overall exposure, which may reduce the risk of toxicity and overdose, without eliminating it entirely.

At low doses, the need for systematic QTc monitoring is less clearly established and should mainly be tailored to individual risk factors and concomitant medications.

Finally, several studies and clinical practices describe outpatient or home initiation in selected patients, provided that titration is cautious and appropriate monitoring is ensured.

How can it be introduced?

Most published studies report doses reaching approximately 10 mg/day within several days to a few weeks. Treatment should be initiated at a low dose and increased gradually, with close clinical monitoring and reassessment after every dose modification.

Examples of reported regimens include an

Initial dose ranging from 1 mg three times daily to 5 mg once daily,

followed, after approximately 1–2 weeks, by doses such as

3 mg three times daily or 10 mg once daily in the evening.

Methadone co-administration: limitations

Methadone co-administration remains an off-label practice in this indication. Although the available clinical data are encouraging, the level of evidence remains limited, with most studies being observational, retrospective, or based on small sample sizes, and very few large randomized controlled trials.

Therefore, this strategy should remain individualized, closely supervised, and regularly reassessed, pending more robust prospective data.

Treillet E, Perceau-Chambard E, Economos G, et al. Low-dose methadone added to another opioid for cancer pain: a multicentre prospective study. Support Care Cancer. 2024;32:716. doi: 10.1007/s00520-024-08835-2. PMID: 39382714.

Hasegawa T, Okuyama T, Suzuki N, et al. Efficacy and safety of combining low-dose methadone with ongoing opioid treatment for uncontrolled cancer pain: an open-label single-arm study. The Oncologist. 2025;30(9):oyaf215. doi: 10.1093/oncolo/oyaf215.

Sato T, Fukutomi A, Kawamura T, Kawakami K, Sato T, Kamo Y, Suzuki T, Hagiya S, Tanaka R. Low-dose add-on methadone for cancer pain management: a retrospective analysis of 102 Japanese patients. Jpn J Clin Oncol. 2025;55(2):123-130. doi: 10.1093/jjco/hyae156.

Duarte FCN, Ferraro LHDC, Ferreira A, Sakata RK. A randomized controlled trial evaluating the analgesic effect of the combination of methadone with morphine for cancer related pain. Clin J Pain. 2021;37(9):664-668. doi: 10.1097/AJP.0000000000000959. PMID: 34265791.

Chary S, Abdul-Razzak A, Galloway L. Ultralow-dose adjunctive methadone with slow titration, considering long half-life, for outpatients with cancer-related pain. Palliat Med Rep. 2020;1(1):119-123. doi: 10.1089/pmr.2020.0034. PMID: 34223466.

Fürst P, Lundström S, Klepstad P, Runesdotter S, Strang P. Improved pain control in terminally ill cancer patients by introducing low-dose oral methadone in addition to ongoing opioid treatment. J Palliat Med. 2018;21(2):177-181. doi: 10.1089/jpm.2017.0157. PMID: 28792784.

Courtemanche F, Dao D, Gagné F, Tremblay L, Néron A. Methadone as a coanalgesic for palliative care cancer patients. J Palliat Med. 2016;19(9):972-978. doi: 10.1089/jpm.2015.0525. PMID: 27399839.

Wallace E, Ridley J, Bryson J, Mak E, Zimmermann C. Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series. J Palliat Med. 2013;16(3):305-309. doi: 10.1089/jpm.2012.0335. PMID: 23391350.